<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516515</url>
  </required_header>
  <id_info>
    <org_study_id>GESRTAKB</org_study_id>
    <nct_id>NCT01516515</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis</brief_title>
  <official_title>A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G&amp;E Herbal Biotechnology Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G&amp;E Herbal Biotechnology Co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum
      undatum plant extract in patient with Actinic Keratosis (AK).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total clearance rate:</measure>
    <time_frame>8-week post-EOT visit (scheduled at Week 24 visit)</time_frame>
    <description>The proportion of patients achieving total clearance of AK lesions in the treatment area (in total of 25cm2 area) at 8-week post-EOT visit (scheduled at Week 24 visit) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial clearance rate</measure>
    <time_frame>24 week</time_frame>
    <description>The proportion of patients achieving ≥ 75% total clinically assessed AK lesion counts out of all target lesions in the treatment area (in total of 25cm2 area) at the post-EOT visit (8 weeks after EOT visit).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>placebo, gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SR-T100 with 2.3% of SM, gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.3% of SM in Solanum undatum plant extract</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo, gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR-T100 with 2.3% of SM</intervention_name>
    <description>2.3% of SM in Solanum undatum plant extract</description>
    <arm_group_label>SR-T100 with 2.3% of SM, gel</arm_group_label>
    <other_name>SR-T100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female; aged ≥ 18 years old.

          2. Patient who accepts to enter the study by signing written informed consent.

          3. Patient has 4 to 8 clinically diagnosed, discrete, non-hyperkeratotic,
             non-hypertrophic AK, located with or without a contiguous 25cm2 areas.

          4. Patient allows biopsy to be performed on selected lesion.

          5. Patient agrees to apply the study medication on prescribed treatment area with an
             occlusive dressing at least 20 hours per day.

          6. Patient agrees photographs to be taken on selected lesion and used as part of the
             study data package.

          7. Patient in good general health condition (performance status ≤ 2 Eastern Cooperative
             Oncology Group (ECOG).

          8. Sexually active female patient with child-bearing potential must take reliable
             contraception method(s) during the participation of the study.

        Exclusion Criteria:

          1. Patient with recurrent invasive squamous cell carcinoma (SCC).

          2. Patient has grossly suspicious or inflamed lymph nodes on physical examination.

          3. Patient has evidence of clinically significant or unstable medical conditions.

          4. Patient has any skin condition in the treatment area that may be made worse by
             treatment.

          5. Patient currently uses or had used on the treatment area(s) OTC retinol products,
             corticosteroids, cryosurgery, curettage, 5-fluorouracil (5-FU), imiquimod, topical
             diclofenac, retinoids, or other topical AK treatments (such as laser abrasion,
             dermabrasion, glycolic acids, or chemical peels) 28 days prior to screening visit.

          6. Patient had received systemic cancer chemotherapy or immunosuppressant; on the target
             evaluation area that psoralen plus UVA therapy, UVB therapy were treated 6 months
             prior to screening visit.

          7. Patient currently uses or has used prednisone and/or prednisolone (≥ 10 mg or the
             equivalent) more than 2 weeks continuously within 12 weeks prior to randomization
             visit.

          8. Engaging in activities involving excessive or prolonged exposure to sunlight.

          9. History of allergy or sensitivity to related compounds or other components of the
             investigational product formulation.

         10. Woman who is pregnant, lactating or planning to become pregnant during the study.

         11. Patient used any investigational drug within 8 weeks prior to the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contour Dermatology &amp; Cosmetic Surgery Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Research Centers</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Clinical Research Collaborative</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates,P.A. The Center for Skin Research</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pflugerville Dermatology Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation, Inc</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>AK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

